History of and Cardiovascular, Cerebrovascular Disease Risk
| | | To ensure that you never miss an issue, please whitelist us. |
|
|
| | | Researchers examined whether semaglutide could reduce the increased risk for type 2 diabetes associated with obesity in an analysis of data from two trials of semaglutide. STEP1 included 1,961 participants with overweight or obesity who received 2.4 mg semaglutide or placebo weekly for 68 weeks. STEP4 included 803 participants with overweight or obesity who all received semaglutide for 20 weeks and then remained on semaglutide or were switched to placebo for 48 weeks. |
|
|
Colleagues conducted a systematic literature review to quantify the overall and type-specific risks for cardiovascular and cerebrovascular diseases, as well as venous thromboembolism in women with a history of GDM. |
| | |
| |
|
|
